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Upregulation of Mrps18a in breast cancer
identified by selecting phage antibody
libraries on breast tissue sections
Karen Marie Juul Sørensen1†, Theresa Meldgaard1†, Connie Jenning Melchjorsen1, Agla J. Fridriksdottir2,
Henrik Pedersen1, Ole William Petersen2 and Peter Kristensen1*
Abstract
Background: One of the hallmarks of cancer is an altered energy metabolism, and here, mitochondria play a
central role. Previous studies have indicated that some mitochondrial ribosomal proteins change their expression
patterns upon transformation.
Method: In this study, we have used the selection of recombinant antibody libraries displayed on the surface of
filamentous bacteriophage as a proteomics discovery tool for the identification of breast cancer biomarkers. A small
subpopulation of breast cells expressing both cytokeratin 19 and cytokeratin 14 was targeted using a novel
selection procedure.
Results: We identified the mitochondrial ribosomal protein s18a (Mrps18a) as a protein which is upregulated in
breast cancer. However, Mrps18a was not homogeneously upregulated in all cancer cells, suggesting the existence
of sub-populations within the tumor. The upregulation was not confined to cytokeratin 19 and cytokeratin 14
double positive cells.
Conclusion: This study illustrates how phage display can be applied towards the discovery of proteins which
exhibit changes in their expression patterns. We identified the mitochondrial protein Mrps18a as being upregulated
in human breast cancer cells compared to normal breast cells.
Keywords: Phage display, Domain antibodies, Breast cancer, Shadow stick selection, Mitochondrial ribosomal
protein s18a
Background
Cancer is a prevalent cause of death, and is estimated to
have been responsible for 8.2 million deaths globally in
2012. Accounting for approximately 521 000 deaths
every year, breast cancer is one of the most common
causes of cancer-related death [1].
Changes in cell metabolism are central to cancer
development [2]. Mitochondria play a central role in
regulating parameters of the metabolism, such as energy
production, production of biosynthetic precursors, redox
status, reactive oxygen species generation, cytosolic
calcium levels, and the initiation of apoptosis. In both
normal cells and cancer cells, changes in these parame-
ters may prompt a shift in the cell state, e.g., from quies-
cent and differentiated to actively proliferating. Increases
and decreases in mitochondrial activity can be mediated
by mutations in genes encoding mitochondrial proteins.
In the context of breast cancer, several studies on
mitochondrial alterations are available and have been
reviewed in [3]. Only a small fraction of mitochondrial
proteins are encoded by the mitochondrial DNA.
Nuclear DNA encodes all other mitochondrial proteins,
including mitochondrial ribosomal proteins (Mrps). This
emphasizes the integrated nature of the cross-talk
between the mitochondria and the nucleus.
Early proteomic analysis of the mammalian mitochon-
drial ribosome reported three variants of Mrps18 [4, 5].
* Correspondence: pk@eng.au.dk
†Equal contributors
1Department of Engineering, Aarhus University, Gustav Wieds Vej 10, 8000
Aarhus C Aarhus, Denmark
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Sørensen et al. BMC Cancer  (2017) 17:19 
DOI 10.1186/s12885-016-2987-5
Although these early studies revealed that members of
the s18 protein family are localized on the surface of the
small subunit (S28) of the mitochondrial ribosome, the
function of these proteins is largely unknown. Recent
data reporting the complete structure of the large mito-
chondrial ribosomal subunit has revealed that Mrps18a
is not located on the small subunit as previously indi-
cated, but on the large ribosomal subunit [6], which
demonstrates the lack of knowledge concerning the
importance and function of Mrps18a. The three variants,
designated Mprs18a, Mrps18b, and Mrps18c, are the
products of three separate genes. The genes are only
25–30% identical, which is comparable to their hom-
ology with their bacterial counterparts [4]. It has been
suggested that there may be different sub-populations of
cells within tissues where the expression levels of the
different Mrps18 variants vary [7]. In 2009, it was shown
that overexpression of human Mrps18b in primary rat
embryonic fibroblasts leads to immortalization. A cell
line derived from these cells, called 18IM, adopted sev-
eral cancer-like characteristics, such as loss of contact
inhibition and anchorage-independent growth. Further-
more, 18IM cells acquired expression of different stem
cell markers [8]. Microarray and Q-PCR analysis of
18IM and three other equivalent cell lines showed up-
regulation of a range of genes involved in mitochondrial
pathways such as energy production, which are charac-
teristic of rapidly proliferating cells [9]. Recently, a study
of overexpression of Mrps18b in human breast and renal
cancer cell lines has shown that Mrps18b results in the
appearance of multinucleated cells [10]. These observa-
tions indicate that Mrps18 family proteins, or at least
Mrps18b, may be involved in neoplastic transformation.
It is widely believed that intertumor heterogeneity
reflects the “cell of origin” as well as the mutational pro-
file of a given cancer cell [11, 12]. Much effort has been
put into unravelling the normal cellular hierarchy of the
human breast, as it is an important step toward under-
standing the “cells of origin” and molecular events that
drive breast cancer. Several populations of cells within
the human breast have been proposed as candidates for
the “cells of origin” of cancer, including stem cells and
progenitors, or transit-amplifying cells. One such candi-
date population was identified in a study performed by
Villadsen et al., and supported by Honeth et al. [13],
where a putative stem cell zone was identified in the
ducts of the normal human breast containing multipo-
tent cells positive for both the luminal epithelial lineage
marker, cytokeratin 19 (K19), and the myoepithelial
lineage marker, cytokeratin 14 (K14) [14].
In this study, we aimed to identify proteins which are
differentially regulated in breast cancer and may there-
fore have a potential use in the diagnosis and/or treat-
ment of breast cancer. Phage display-mediated selections
of human domain antibodies were performed against
ductal regions containing K19+/K14+ cells in normal
breast tissue cryostat sections using the shadow stick
selection technique [15, 16] adopted from [17–19]. Here,
a recombinant antibody library, displayed in genetic
fusion with the filamentous bacteriophage protein 3 [20],
is allowed to bind to antigens presented on the tissue
sections. Compared to selection on intact cells obtained
from circulation or cell culture, the tissue sections allow
all cellular compartments to be targeted, as the sections
normally have a thickness of 4–8 μM. Following removal
of non-binding phage antibodies by washing, the target
cells in the tissue are covered by a shadow stick and the
tissue section is illuminated by UV-C light. The UV-C
light causes crosslinking in the phage genome, resulting
in phage particles incapable of replication after infection.
Phage particles covered by the shadow stick are pro-
tected from the UV-C light and remain able to replicate
after infection. In this way, phage display selection
becomes a discovery tool in the search for proteins
which are differentially regulated between distinct cell
populations, which may represent novel biomarkers.
A potentially interesting antigen, Mrps18a, emerged as
the cognate antigen of one of the selected phage anti-
bodies. Although the functions of this particular protein
are currently unexplored both in the context of the
normal cell state as well as in cancer cells, we found that
the expression of Mrps18a is upregulated in breast
cancer cells compared to normal cells. Mrps18a cannot
be considered a unique biomarker for K19 and K14 posi-
tive cells, as it is found in both normal and cancer cells.
However, its increased expression in cancer cells is
explained by the increased energy metabolism of cancer
cells, and it may pave the way for new diagnostic and
therapeutic routes to be explored.
Methods
Tissue sections
Biopsies of healthy human breast tissue and breast
cancer tissue were obtained from five patients (P636,
P659, P722, P727, and P819) undergoing reduction
mammoplasty and three cancer patients (P757, P942,
and P949), respectively. The use of human material has
been reviewed by the Regional Scientific Ethical Co-
mmittees (Region Hovedstaden) and approved with
reference to H-2-2011-052 and H-2-2010-051. Informed
consent was obtained from each patient regarding the
collection and use of tissue. Cryostat sections (8 μm)
were prepared as described by [21]. All tissue sections
were fixed in methanol for 5 min at −20 °C.
Target area identification
In preparation for selection, tissue sections were stained
by immunohistochemistry (IHC) with antibodies against
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K19 and K14 and detected with Alexa Flour A568 and
A488 conjugated isotype specific goat anti-mouse anti-
bodies, respectively. For details on the antibodies, see
Tables 1 and 2.
One tissue section from each patient was mounted with
Fluoromount (Sigma-Aldrich), and areas containing rare
K19+/14+ cells were identified. Only patient samples con-
taining 1–2 areas with 2–10 luminal positioned K19+/14+
cells residing in ductal regions were used for selections.
Selection
The tissue section was blocked for 1 h in 4% Marvel dried
skim milk powder (MPBS). The tissue section was then
incubated with the Predator single domain library [22] in
a slide container containing 20 mL 2% MPBS for 1½ h on
a turntable under gentle agitation and for 1½ h without
agitation. Approximately 1012 phage particles of the
Predator library were applied [22]. The tissue section was
washed twice for 10 min in PBS and twice for 10 min in
PBS with 10% glycerol (PBSG) under gentle agitation. The
tissue section was dried except the target area, which was
kept moist with PBSG. Using brightfield microscopy, a
custom made shadow stick (~80 μm) was positioned
above the target area. Shadow sticks were prepared as
previously described [23]. The tissue section was exposed
to UV-C light (254 nm) for 10 min using a UV-C source
(model UVSL-14P from UVP, Upland) positioned approxi-
mately 5 cm above the tissue section. Phage particles were
eluted with 15 μL trypsin (1 mg/mL) for 10 min. Trypsin
was aspirated and transferred to 50 μL ice cold foetal
bovine serum. Subsequently, the target area was washed
15 times with 50 μL PBSG. This liquid was transferred to
the eluate before storage overnight at −20 °C. The trypsi-
nated phages were propagated in E. coli and single col-
onies were cultured in a 96-well plate as described by [23].
Phage antibody ELISA
Phage antibodies were produced by superinfection with
the KM13 helper phage [24]. This was performed in 96-
well format for screening and in 50 mL cultures for
ELISA with dilution arrays of monoclonal phage anti-
bodies respectively followed by precipitation with 20%
poly ethylene glycol (PEG) 6000, 2.5 M NaCl. Phage
titers from 50 mL cultures were estimated by calculation
using absorbance measured at 269 and 320 nm as
described by [25].
Costar 96 well culture plates (Corning) with luminal
breast cells enriched for K19+/K14+ cells were prepared
by FACS and short term culturing. Luminal cells were
initially sorted from normal breast tissue (source as de-
scribes for tissue sections) with EpCAM, then cultured
in FAD2 medium consisting of Ham’s F12 : DMEM
mixed in a 1:3 ratio (Tan DW, 2013), and 5% FCS (Liu
X, 2012). The cells were cultured on a feeder layer
of mouse fibroblasts to minimize the arisal of basal
K14+ cells. Sorting of EpCAM+/CD271+ cells from
these cultures resulted in a population enriched for
K19+/K14+ cells. These were cultured in FAD2 medium in
collagen coated flasks. K19+/K14+ and K19+ cells were
represented approximately 1:1. The cells were seeded in
96-wells, approximately 10–20 000 cells/well, and cultured
3–5 days before fixation for 10 min with 3.7% formalin,
followed by 10 min with 0.1% triton X-100. The plates
were dried overnight at 37 °C.
For screening, 50 μl 4% MPBS and 50 μL of the indi-
vidual PEG precipitated phage antibodies were trans-
fered to a cell coated 96-well plate. For ELISA with
dilution arrays of monoclonal phage antibodies, a six
pointed 10-fold dilution series was prepared. From this,
100 μL was transferred to the 96-well plate resulting in
concentrations ranging from 1011 phages/well to 107
phages/well. As a positive control, the phage scFv anti-
body 52 was used [26]. This phage antibody has been
reported to have affinity towards at least 14 different cell
lines, among these breast cancer cell line MCF7 [26]. As
a negative control, a phage scFv antibody specific to
foetal Epsilon-haemoglobin, DAb1, was included [27].
For both screening and ELISA with dilution arrays,
bound phage antibodies were detected with HRP con-
jugated M13 phage antibody (GE healthcare) 1:3000
and TMB Plus “Ready-to-use” substrate solution
(Thermo, Fischer Scientific) according to the ma-
nufacturer’s protocol. The chromogenic reaction was
stopped after 10–15 min by addition of 50 μL 1 M
H2SO4. Absorbance (OD450) was read on a Bio-Rad
Model 550 microplate reader (Bio-Rad) with subtrac-
tion of background (OD655).
Expression of single domain antibody (dAb) in E. coli
For expression of soluble dAb, the sequence encoding
BC5 was sub-cloned from phagemid into pET22b-
MycHis, a modified version of pET22b (Merck, KGaA),
Table 1 Primary antibodies used for IHC
Description Isotype Dilution Source
Mouse monoclonal Anti-K14 IgG3 1:50 Leica Biosystems, NCL-L-LL002
Mouse monoclonal Anti-K19 IgG2a 1:100 Abcam, ab7754
dAb - ̴250 μg/mL -
dAb-rFc - 40–100 μg/mL -
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using NcoI and NotI (FastDigest, Fermentas) according
to the manufacturer’s protocol. This expression plasmid
was transformed into BL21 Gold DE3 (Aglient Tech-
nologies). For expression, 200 mL exponentially growing
cultures were set up in TB growth medium supple-
mented with 100 μg/mL ampicillin and 4% w/v glucose
at 37 °C, 200 rpm. At an OD600 of approximately 0.6–
0.8, protein expression was induced by exchange of
growth medium to TB containing 100 μg/mL ampicillin
and 1 μM IPTG and incubated 18–20 h at 18 °C,
200 rpm. Protein was precipitated using 30% w/v ammo-
nium sulphate. Pelleted protein was resuspended in
20 mL Protein A binding buffer TBS (50 mM Tris,
150 mM NaCl) pH 8.0 added 0.1 mM DNase (Roche).
The protein suspension was sterile filtered (0.45 μm)
before affinity purification on HiTrap Protein A column
(GE Healthcare) according to the manufacturer’s pro-
tocol, except eluted with 2.5% acetic acid. Purified
antibody fragments were transferred to TBS, pH 7 by
dialysis. A purity over 95% was confirmed by SDS-
PAGE, and the protein concentration was assessed with
a NanoDrop 1000 (Thermo, Fisher Scientific).
Expression of dAb with rabbit Fc-domain (dAb-rFc) in
L. tarentolae T7-TR
In order to express soluble dAb-rFc, the sequence en-
coding BC5 antibody was sub-cloned from phagemid
into pMJ_LEXSY-rFc vector, and expressed and purified
as described [28].
Immunohistochemistry
For initial IHC, tissue sections were blocked in Ultravi-
sion Block (Thermo scientific) for 1 h. Incubation with
primary antibody (Table 1) in a total volume of 100 μL
Ultra Vision Block with 10% goat serum (Sigma Aldrich)
was performed overnight at 4 °C in a humidity box. In-
cubation with fluorescent secondary antibodies (Table 2)
were performed for 30 min in 100 μL Ultra Vision Block
with 10% goat serum. Flouromount (Sigma-Aldrich) was
used for mounting. A frozen tissue microarray with
5 μm sections (BioChain®, Cat. T6235086-1) was blocked
and stained as described above. Fluorescence microscopy
was performed with a Leica DMI 3000 B microscope
with Cell B imaging software.
Antigen identification–protein macroarray
Screening of a UniPEx1 protein macroarray (BioScience
ImaGenes) was performed according to the manufac-
turer’s protocol with purified recombinant antibody,
either dAb or dAb-rFc. Briefly, the activated membrane
was blocked with 5% BSA for 1 h before incubation
overnight with 250 μg dAb or 125 μg dAb-rFc. Detection
was performed by incubation for 2 h with secondary anti-
body; Monoclonal Anti-c-Myc −Cy3™ (Sigma-Aldrich)
1:2000 or Goat anti-Rabbit-IgG-Cy5 (Abcam, ab6564)
1:8000. The membrane was scanned with a Typhoon
TRIO variable mode imager (Amersham Biosciences).
Antibody binding to the proteins on the array was evalu-
ated using an in-house developed Matlab program. The
immobilised proteins were situated on the membrane in
defined duplicated patterns arranged in squares consisting
of 3x3 spots with a central ink dot. By evaluating the
intensities of different spots compared to the background,
as well as their positions, the program created a list of
possible antigen hits listed from highest to lowest inten-
sity. Only hits detected with both dAb and dAb-rFc
formats were considered. Furthermore, hits detected
only once despite being spotted several times in duplex
were omitted.
Indirect ELISA with Mrps18a
MRPS18A cDNA was purchased (Source BioScience,
IRAUp969D0453D) and the sequence verified. The
insert was sub-cloned into pETM11 after PCR amplifica-
tion using primers inserting recognition sequences for
the restriction enzymes NotI and NcoI. This allowed for
cytosolic expression in BL21 Gold DE3 and subsequent
affinity purification under native conditions on Ni-NTA
Superflow Beads (QIAGEN) according to manufacturer’s
protocol.
A 96-well MaxiSorp plate (Thermo, Fisher Scien-
tific) was coated with purified Mrps18a in concentra-
tions ranging from 1 to 1500 ng in TBS, pH 7.5, per
well and blocked with 2% BSA. The plate was incu-
bated for 2.5 h under gentle agitation with 100 μg/mL
or 200 μg/mL dAb. Bound antibodies were detected
with HRP conjugated Anti-c-Myc (not commercial)
1:400. TMB “Ready-to-use” substrate was applied as
described above.
Table 2 Secondary antibodies used for IHC
Description Flourophore Isotype specificity Dilution Source Detection of
Goat anti-mouse A488 IgG3 1:500 Invitrogen, A21151 CK14
Goat anti-mouse A350 IgG2a 1:250 Invitrogen, A21130 CK19
Goat anti-mouse A488 IgG2a 1:500 Invitrogen, A21131 CK19
Mouse anti-human c-Myc Cy3 IgG1 1:250 Sigma-Aldrich, C6594 dAb
Goat anti-rabbit A488 IgG (H + L) 1:400 Invitrogen, A11008 dAb-rFc
A Alexa Fluor® fluorescent dye
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Far western blot analysis
Purified Mrps18a, was run in a standard SDS-PAGE
under reducing conditions and then electro blotted onto
a PVDF membrane using the traditional sandwich
method. Denaturing and renaturing of protein in the
membrane was facilitated by subsequent steps of incuba-
tion with AC buffers with decreasing concentrations of
guanidine–HCl (6 M–0 M) as described [29]. Subse-
quently, the membrane was incubated with 10 μg BC5
(dAb-rFc), followed by HRP conjugated swine anti-rabbit
(DAKO) 1:4000. Detection was carried out with an ECL
detection kit (Amersham Biosciences).
Results
Selection using the shadow stick method
Selections of phage displayed antibody libraries were
performed on normal breast tissue sections containing a
low frequency of K19+/K14+ cells lining the ductal
lumen (Fig. 1a–d). Designation and localisation of target
areas for selection and the positioning of the shadow
stick above the target area are depicted in (Fig. 1e–f ). A
total of eight selections with the Predator single domain
antibody library [22] yielded 93 clones. These were
picked and cultured in a 96-well plate. In order to re-
duce the panel of domain antibodies for further analysis,
the individual clones in the master plate were screened
by monoclonal phage antibody ELISA on short term
cultured primary breast cells enriched for K19+/K14+
cells (Additional file 1: Figure S1). A number of clones
showed binding to these cells. In this study, we chose to
focus on the domain antibody called BC5, since it exhib-
ited the most interesting binding pattern in IHC stain-
ings (as shown later) and, more importantly, this
antibody is currently the only antibody for which the
cognate antigen has been identified.
BC5 binds K19+/K14+ cells in ELISA
To evaluate the binding of the phage domain antibody
BC5, ELISA with serial dilutions of monoclonal phage
antibodies was carried out on K19+/K14+ enriched cells
(Fig. 2). For comparison, two other phage domain anti-
bodies from the same selections are included in the
figure. One of these is BC1, which binds strongly to K19
+/K14+, but exhibits a less interesting staining pattern
in IHC; it binds an antigen which is highly expressed in
luminal cells and with clear staining into the stroma
(Additional file 2: Figure S4). The other phage dAb,
BC8, does not bind K19+/K14+ cells. The phage scFv
antibody fragments 52 and DAb1 were included as posi-
tive and negative controls, respectively. BC5 binds to the
K19+/K14+ enriched cells, as can be seen in Fig. 2.
The cognate antigen of BC5 is upregulated in breast
cancer
For further analysis, BC5 was sub-cloned into the vectors
pET22b-MycHis and pMJ_LEXSY-rFc for expression of
Fig. 1 Example of target area identification and positioning of shadow stick during selection. a Overview of the target area. b–d Target area in
close proximity. Red and green indicates K19 and K14 immunofluorescence respectively. The K19+/K14+ target cells are encircled in (d). e The
exact same area on a consecutive neighboring slide. Note that the slide has been inverted in order to position shadow stick above cells.
f Positioning of shadow stick during selection
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soluble domain antibodies with c-Myc tag and His-tag
(dAb) or dimeric soluble domain antibodies with rabbit
Fc-region (dAb-rFc) (data not shown). The availability of
two different formats allows for detection using both the
affinity tags or the Fc region of rabbit IgG, and thereby
provided us with the ability to validate the binding using
different formats.
IHC with both formats of soluble antibody in combin-
ation with a commercial anti-K19 antibody were carried
out on five different normal breast tissue biopsies and
three different breast cancer biopsies containing varying
amounts of K19+/K14+ cells. The staining pattern of the
domain antibody BC5 in normal tissue was compared to
staining for cytokeratin 19 (Fig. 3). The staining intensities
of the individual cells varied, not necessarily coinciding
with the K19+ intensity of a given cell. In the breast cancer
biopsies, a larger number of cells were stained by BC5.
Furthermore, the staining followed that of K19 (not
shown). Negative control stainings with secondary anti-
body alone or DAb1 revealed no unspecific staining
(Additional file 3: Figure S2). To further assess the stain-
ing characteristics of BC5, IHC on a frozen tissue micro-
array with 37 different breast cancer biopsies and three
normal breast biopsies was performed with the dAb
format of BC5 as well as commercial mouse anti-K19 and
mouse anti-K14 antibodies. Concurrent with the initial
IHCs on single biopsies, the staining pattern of BC5 on
normal breast tissue varied from biopsy to biopsy (Fig. 4A).
The biopsy in Fig. 4A(a) shows an area with only few K19
+ or K14+ cells stained by BC5, while the biopsy in
Fig. 4A(b) displays an area generally stained and a cluster
of intensively stained cells. However, when observing the
Fig. 2 ELISA with dilution arrays of monoclonal phage antibodies on K19+/K14+ enriched cells. The y-axis depicts the ELISA signal in arbitrary units
for serial dilutions of phages antibodies. The x-axis depicts the phage titer in the dilution series. Included in the figure are data for the three
phage domain antibodies BC1, BC5 and BC8 as well as those of the positive and negative controls (scFvs)
Fig. 3 IHC with BC5 dAb-rFc and anti-K19 on normal breast tissue. a Detection of commercial anti-K19 (red). b Detection of BC5 (green) in the
same area. A fraction of the K19+ cells was also stained by BC5. Biopsy P659
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37 cancer biopsies, most of the cancer cells were stained
by BC5 (Fig. 4B). The degree to which BC5 stained cancer
cells was rather consistent from biopsy to biopsy through-
out the microarray. However, before conclusive data can
be obtained concerning sub-populations and relation to
tumor type etc., a large scale study should be performed.
Nonetheless, these results show that BC5 recognises an
antigen with increased expression in some breast cancer
cells, as opposed to a lower and more heterogeneous
expression pattern in normal breast cells. Therefore, the
cognate antigen of BC5 must be up-regulated during
breast cancer tumorigenesis. In order to examine this
further, the cognate antigen of BC5 was identified.
BC5 recognizes mitochondrial ribosomal protein S18A
To exclude any cross reactivity of BC5 towards K19, an
ELISA on purified K19 protein with BC5 dAb was
performed. BC5 did not bind K19 (results not shown).
This was further supported by the staining of K19−/K14+
cells with BC5 (Fig. 4B(d)).
In order to reveal the cognate antigen of BC5, a
protein macroarray containing bacterially expressed
cDNA clones representing more than 7000 distinct
human proteins (originating from foetal brain, T-cells,
lung, and colon) was incubated with the dAb format of
BC5. By means of an in-house developed image analysis
program, the mean intensity of the different spots on the
Fig. 4 IHC on tissue microarray with BC5 dAb on normal breast and breast cancer tissue. A Normal tissue. The rows a and b represent two
different normal breast biopsies with pictures from left to right representing staining with anti-CK19 (blue), anti-K14 (green) and BC5 dAb (red).
B Breast cancer tissue. Each of the rows c–f represents different biopsies with pictures from left to right representing staining with anti-CK19
(blue), anti-K14 (green), BC5 dAb (red) and a merge of K14 and BC5. Scale bars 50 μm
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protein macroarray was compared to the background,
and a scored list ranging from the highest to lowest in-
tensity of possible antigen hits was generated (Additional
file 4: Figure S3). The macroarray was subsequently
incubated with the dAb-Fc format. This was performed
in order to validate the truly positive antigen hits. A
single common hit was obtained, representing mito-
chondrial precursor ribosomal protein S18A (MRPS18A)
cDNA. In order to verify the binding of BC5 to Mrps18a,
the cDNA clone was sub-cloned into the pETM11 expres-
sion vector. Indirect ELISA with two different concentra-
tions of the dAb format of BC5 on different amounts of
purified Mrps18a (Fig. 5A) showed binding of BC5 to
Mrps18a. BC6, another domain antibody from the current
selection, was included in the experiment (Fig. 5A(d)).
BC6 did not bind Mrps18a, which confirmed that the
binding of BC5 to Mrps18a was related to the antigen
binding region of BC5 and not to the Predator single
domain scaffold. BC5 did not recognise Mrps18a in a
standard western blot (results not shown). However, in a
far western blot analysis of Mrps18a (Fig. 5B), BC5
showed clear recognition of Mrps18a. By performing far-
western blot analysis of extracts from MCF7 cells (whole
cell, cytoplasmic and mitochondrial fractions), three bands
in the whole cell and two in the mitochondrial fraction
are observed (Additional file 5: Figure S5). The upper
band corresponds to Mrps18a, while the lower bands may
constitute degradation products. The high molecular
weight band observed in the cytoplasmic fraction may be
a result of loading different amounts of total protein in
the different lanes, as a similar band is not observed in the
whole cell extract. Altogether, this indicates that BC5
recognises a conformational epitope on Mrps18a, and that
the recognition is specific.
Discussion
This study describes the identification of Mrps18a as an
antigen which exhibits increased expression by some
human breast cancer cells compared to normal cells.
Traditionally, changes in the expression of proteins in
cancer cells have been studied using both expression
studies looking at the mRNA levels and proteomics
Fig. 5 BC5 has affinity towards Mrps18a. A Indirect ELISA with 0–1500 ng/well coated Mrps18a. a Triplicates of BC5 dAb,10 μg/well. b Triplicates
of BC5 dAb, 20 μg/well. c Triplicates of BC6 dAb, 10 μg/well. d control of unspecific background from HRP conjugated anti-c-Myc alone against
coated Mrps18a. B Far western blot analysis of Mrps18a performed with (+) or without (−) BC5 dAb as primary antibody. Bars represent
the mean ± SD. When comparing BC5 dAb, 10 μg/well with BC6 dAb, 10 μg/well the p-value for the signal at a Mrps18a coating concentration of
1000 ng/well is P < 0.01
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using 2D gels and mass spectrometry to identify changes
at the proteome level. Here, we have used the selection
of recombinant phage antibody libraries as a discovery
tool to identify proteins which exhibit differential ex-
pression. The putative stem cell niche on which we have
selected contained K19+/K14+ cells, which are candidate
cells of origin of breast cancer [14]. The principle of the
selection method relies on the retrieval of phage-
displayed antibody fragments binding to a minute area
of interest in a tissue section. Using the shadow stick,
only phages binding to the target area were able to
replicate in E. Coli. This method yields a low output of
clones from each selection compared to traditional
selections, while generating a relative high frequency of
phage antibodies binding to unique or upregulated anti-
gens [23]. Important for this approach is the choice of
screening material, i.e., the nature of the cells on which
the selected antibodies are tested. When targeting rare
cells there is always a compromise between availability
of suitable cells and the extent to which they resemble
the target cells. In this study, a limiting factor was the
availability of primary K19+/K14+ cells for screening pur-
poses. Here, short-term-cultured K19+/K14+ cells were
used for screening. The use of short-term cultivation
limited the total number of cells available for the initial
ELISA testing, preventing triplicate measurements. The
initial ELISA was only used as a means for defining the
phage antibodies which were to be considered for
further analysis. When performing ELISA with the anti-
body presented on the phage particle on cultured cells,
care must always be taken. The data can vary greatly
depending on the number of cells remaining in each 96
well after ELISA, the display level of the individual
phage antibodies, the background binding due to phage
coat proteins binding to the ELISA well, etc. The signal
intensities in the ELISA screenings were low. However,
unlike ELISA against purified proteins, low signal in
ELISA against cells is expected. This is primarily because
unique or upregulated antigens in the targeted cells are
not necessarily expressed at high levels, or at all, in the
cells used for screening. Furthermore, some of the
selected phage antibodies may bind the antigens with
low affinity, regardless of the relevance of the antigens
in question.
From our selection, the antibody BC5 was isolated,
and its cognate antigen was identified as Mrps18a. Other
MRPs such as MrpL11, MrpL12 and MrpL28 have been
reported to be differentially expressed in tumour cells or
tissue [30, 31]. Knock-down of MRPL28 in pancreatic
tumour cells resulted in decreased mitochondrial activ-
ity, increased glycolysis, and accelerated growth in vivo,
a phenomenon commonly observed in cancer cells (the
Warburg effect) [31]. This shows that changes in the
expression of Mrps affect the mitochondrial metabolism
and thereby many of the parameters that control cell
state (and, in turn, cancer progression).
Furthermore, it has been observed that some Mrps
have functions in addition to being involved in mito-
chondrial translation. For example, Mrps29, another
protein component of the small mitochondrial ribosomal
subunit, binds GTP and may be involved in the control
of apoptosis [32, 33]. In addition, it has been reported
that Mrps18b specifically binds to the viral transforming
protein, EBNA-6, which targets Mrps18b to the nucleus
in EBV-transformed lymphoblastoid cells. In the nucleus,
Mrps18b binds retinoblastoma protein, which releases
e2F1. Hence, Mrps18b may facilitate a lift of the RB-
dependent block of S-phase entry [34].
A specific role for Mrps18a in cancer has not been
identified until now. Due to the low level of sequence
similarity in the S18 protein family, functional conserva-
tion cannot be assumed.
At present, the focus of research is turning towards
elucidating the role of mitochondria in cancer. Breast
cancer markers and cancer markers in general are re-
quired for the further advancement of diagnostic and
treatment strategies.
Conclusion
This study demonstrates the application of phage display
as a tool for the discovery of proteins which change their
expression in breast cancer. The shadow stick method
allows the selection of antibodies binding to antigens
expressed in specific areas within a given tissue, e.g. a
stem cell niche. In this study, we identified Mrps18a as a
putative breast cancer marker using this method. IHC
analysis showed that Mrps18a is upregulated in human
breast cancer cells compared to normal cells, indicating
that Mrps18a may be involved in oncogenesis. Further
investigation will clarify the role of Mrps18a in oncogenesis
and its relevance as a clinical biomarker.
Additional files
Additional file 1: Figure S1. Screening by monoclonal phage
antibody ELISA on K19+/K14+ enriched breast cells. Phage antibodies
showing the highest signal are presented. The y-axis depicts the
ELISA signal in arbitrary units. The x-axis depicts clone name of the
phage antibody. (TIF 207 kb)
Additional file 2: Figure S4. IHC with BC1 dAb and anti-K14. a, Detection
of BC1 (red). b, Detection of commercial anti-K14 (green) in the same area.
c, overlay of a and b. Biopsy P727. (TIF 291 kb)
Additional file 3: Figure S2. IHC controls. a–c, Example of control
staining with secondary antibody Anti-C-Myc-Cy3 (red) alone, on cancer
tissue (P757). From left to right the pictures show immunofluorescence in
the blue, green and red range respectively. d–e, Example of control
staining with the scFv antibody epsilon, which also was used as a
negative control during screening and validation of selected antibodies.
From left to right the pictures show immunofluorescence in the blue,
green and red range respectively. (TIF 4987 kb)
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Additional file 4: Figure S3. Screenshot of image analysis of protein
macroarray using the in-house designed program. Upper part: A scan
imaged of the protein macroarray membrane with anenlarged area to
depict the pattern of proteins spotted on the membrane. Lower part:
Example of the generated list of possible antigen hits. (TIF 14575 kb)
Additional file 5: Figure S5. Far-western blot of MCF7 cells using BC5
sdAb-rFc as primary antibody and swine anti-rabbit(HRP) as seconday
antibody. Lane 1 contain whole extracts of MCF7 cells while Lane 2 and
Lane 5 contain the cytoplasmic and mitochondrial fraction of MCF7 cells.
(TIF 291 kb)
Abbrevations
18IM: Immortalised primary rat embryonic fibroblast cell line over expressing
mrps18b; HRP: Horseradish peroxidase; IHC: Immunohistochemestry;
K14: Cytokeratin 14; K19: Cytokeratin 19; Mrp: Mitochondrial ribosomal
proteins; Mrps18a: Mitochondrial ribosomal protein s18a
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